VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a note issued to investors on Thursday. The firm set a “sell” rating on the stock.

Separately, Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

VolitionRx Price Performance

Shares of VNRX opened at $0.70 on Thursday. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.23. The stock has a market cap of $64.57 million, a PE ratio of -1.94 and a beta of 1.10. The firm has a 50-day simple moving average of $0.69 and a two-hundred day simple moving average of $0.68.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC lifted its holdings in VolitionRx Limited (NYSE:VNRX) by 78.8% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.